Peter L Gibbons
Overview
Explore the profile of Peter L Gibbons including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
51
Followers
0
Related Specialties
Related Specialties
Co-Authors
Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel K, Batty K, Moore B, Gibbons P, Kirkpatrick C
J Antimicrob Chemother
. 2014 Apr;
69(8):2155-63.
PMID: 24777899
Objectives: To develop a mechanism-based model that describes the time course of the malaria parasite in infected mice receiving a combination therapy regimen of dihydroartemisinin and piperaquine. Methods: Total parasite...
2.
Patel K, Batty K, Moore B, Gibbons P, Bulitta J, Kirkpatrick C
Antimicrob Agents Chemother
. 2012 Nov;
57(1):508-16.
PMID: 23147722
Murine models are used to study erythrocytic stages of malaria infection, because parasite morphology and development are comparable to those in human malaria infections. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) models for antimalarials...
3.
Batty K, Gibbons P, Davis T, Ilett K
Am J Trop Med Hyg
. 2008 Apr;
78(4):641-2.
PMID: 18385362
Pharmacokinetic properties of dihydroartemisinin (DHA) were determined in mice given 100 mg/kg intraperitoneal DHA. Half-life, CL/F, and V/F were 25 min, 61.3 L/hr/kg, and 36.3 L/kg in malaria-infected mice and...
4.
Gibbons P, Batty K, Barrett P, Davis T, Ilett K
Int J Parasitol
. 2007 Jun;
37(14):1569-76.
PMID: 17585920
Antimalarial treatment strategies based on in vitro studies are limited by the paucity of pharmacodynamic information for dosage regimen design. We postulated that a murine model could be used for...